From the Research
Mounjaro (tirzepatide) is not contraindicated in patients with Neuroendocrine Tumors (NETs), but caution is advised, particularly for those with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, as suggested by recent studies 1, 2. The medication's prescribing information does not list NETs as a specific contraindication. However, healthcare providers should exercise clinical judgment when prescribing tirzepatide to patients with a history of NETs, particularly those of thyroid origin. This caution stems from findings in rodent studies where GLP-1 receptor agonists (a component of tirzepatide's mechanism) were associated with thyroid C-cell tumors. While this risk has not been established in humans, and tirzepatide works through both GLP-1 and GIP receptors, monitoring is prudent.
Some key points to consider when making treatment decisions include:
- Patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use tirzepatide, as the potential risks may outweigh the benefits, as discussed in studies such as 3 and 4.
- For patients with other types of NETs, treatment decisions should be individualized, weighing potential benefits against theoretical risks, with appropriate follow-up monitoring of tumor markers or imaging as clinically indicated, as suggested by recent research 1, 2.
- The use of tirzepatide in patients with NETs requires careful consideration of the potential risks and benefits, and healthcare providers should be aware of the latest research and guidelines when making treatment decisions, such as those outlined in 5.
Overall, while Mounjaro (tirzepatide) is not contraindicated in patients with NETs, caution and careful consideration are necessary to ensure the best possible outcomes for these patients, as supported by the latest evidence 1, 2, 5.